|
Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
|
|
Consulting or Advisory Role - Janssen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
|
|
Consulting or Advisory Role - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Takeda |
Honoraria - Genmab; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Genmab; Janssen-Cilag; Takeda |
Research Funding - Genmab (Inst); Janssen-Cilag (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Takeda |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
|
|
Honoraria - Amgen; Celgene |
Consulting or Advisory Role - Amgen; Celgene |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Sanofi |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst) |